It Takes Two to Make It Right: Dual Biologic and Small Molecule Therapy for Treatment-Refractory Pediatric Inflammatory Bowel Disease

Combination Biologic Therapy in Inflammatory Bowel Disease: Experience from a Tertiary Care Center

(2020) Lukasz Kwapisz et al.   Clinical Gastroenterology and Hepatology

Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature

(2020) Christine Olbjørn et al.   PEDIATRIC DRUGS

Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center

(2019) Judy R. Dayan et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis

(2019) Davide Giuseppe Ribaldone et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease

(2019) Michael T. Dolinger et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis

(2018) Siddharth Singh et al.   Journal of Crohns & Colitis

Management of paediatric patients with medically-refractory Crohn’s disease using Ustekinumab: A multi-centred cohort study

(2018) Mallory Chavannes et al.   Journal of Crohns & Colitis

Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease

(2016) Máire A. Conrad et al.   INFLAMMATORY BOWEL DISEASES

A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease

(2014) Elaheh Vahabnezhad et al.   INFLAMMATORY BOWEL DISEASES

Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in Children

(2012) Jeffrey S. Hyams et al.   GASTROENTEROLOGY